- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00552058
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
10. Juli 2018 aktualisiert von: UCB Pharma
Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
439
Phase
- Phase 3
Erweiterter Zugriff
Verfügbar außerhalb der klinischen Studie.
Siehe erweiterter Zugriffsdatensatz.
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Adelaide, Australien
-
Bankstown, Australien
-
Clayton, Australien
-
Fitzroy, Australien
-
Fremantle, Australien
-
Garran, Australien
-
-
New South Wales
-
Concord, New South Wales, Australien
-
-
Victoria
-
Box Hill, Victoria, Australien
-
Footscray, Victoria, Australien
-
Parkville, Victoria, Australien
-
-
-
-
-
Bonheiden, Belgien
-
Brussels, Belgien
-
Gent, Belgien
-
Leuven, Belgien
-
Liege, Belgien
-
Roeselare, Belgien
-
-
-
-
-
Curitiba, Brasilien
-
Goiania, Brasilien
-
Porto Alegre, Brasilien
-
Rio de Janeiro, Brasilien
-
Santo-Andre, Brasilien
-
Santos, Brasilien
-
Sao Paulo, Brasilien
-
-
MG
-
Belo-Horizonte, MG, Brasilien
-
-
-
-
-
Santiago, Chile
-
Vina del Mar, Chile
-
-
-
-
-
Berlin, Deutschland
-
Frankfurt, Deutschland
-
Freiburg, Deutschland
-
Homburg, Deutschland
-
Jena, Deutschland
-
Kiel, Deutschland
-
Munchen, Deutschland
-
Ulm, Deutschland
-
Wilhelmshaven, Deutschland
-
-
-
-
-
Tallin, Estland
-
Tartu, Estland
-
-
-
-
-
Mikkeli, Finnland
-
-
-
-
-
Beer Sheva, Israel
-
Haifa, Israel
-
Holon, Israel
-
Jerusalem, Israel
-
Kfar Saba, Israel
-
Petha Tikva, Israel
-
Rehovot, Israel
-
Tel Aviv, Israel
-
Zerifin, Israel
-
-
-
-
-
Bologna, Italien
-
Padova, Italien
-
Roma, Italien
-
-
-
-
-
Calgary, Kanada
-
-
Alberta
-
Edmonton, Alberta, Kanada
-
-
British Columbia
-
Kelowna, British Columbia, Kanada
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada
-
-
Ontario
-
Hamilton, Ontario, Kanada
-
Kingston, Ontario, Kanada
-
London, Ontario, Kanada
-
Toronto, Ontario, Kanada
-
-
-
-
-
Riga, Lettland
-
Valmiera, Lettland
-
-
-
-
-
Auckland, Neuseeland
-
Christchurch, Neuseeland
-
Hamilton, Neuseeland
-
-
Auckland
-
Milford, Auckland, Neuseeland
-
-
Wellington
-
Newton, Wellington, Neuseeland
-
-
-
-
-
Czestochowa, Polen
-
Lodz, Polen
-
Warszawa, Polen
-
Wroclaw, Polen
-
-
-
-
-
Bucharest, Rumänien
-
Cluj Napoca, Rumänien
-
Constanta, Rumänien
-
-
-
-
-
Kazan, Russische Föderation
-
Moscow, Russische Föderation
-
St. Petersburg, Russische Föderation
-
-
-
-
-
Hradec Kralove, Tschechien
-
Hradek Kralove, Tschechien
-
Praha 7, Tschechien
-
Usti Nad Orlici, Tschechien
-
Zlin, Tschechien
-
-
-
-
-
Dniepropetrovsk, Ukraine
-
Donetsk, Ukraine
-
Kiev, Ukraine
-
Kyiv, Ukraine
-
Lviv, Ukraine
-
Simferopol, Ukraine
-
-
-
-
-
Budapest, Ungarn
-
Gyor, Ungarn
-
Nagykanizsa, Ungarn
-
Szeged, Ungarn
-
Szombathely, Ungarn
-
-
-
-
Alabama
-
Pell City, Alabama, Vereinigte Staaten
-
-
Colorado
-
Colorado Springs, Colorado, Vereinigte Staaten
-
Lakewood, Colorado, Vereinigte Staaten
-
Littleton, Colorado, Vereinigte Staaten
-
-
Florida
-
Hollywood, Florida, Vereinigte Staaten
-
Jacksonville, Florida, Vereinigte Staaten
-
New Port Richey, Florida, Vereinigte Staaten
-
Winter Park, Florida, Vereinigte Staaten
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten
-
-
Louisiana
-
Metairie, Louisiana, Vereinigte Staaten
-
Monroe, Louisiana, Vereinigte Staaten
-
-
Maryland
-
Annapolis, Maryland, Vereinigte Staaten
-
Towson, Maryland, Vereinigte Staaten
-
-
Michigan
-
Chesterfield, Michigan, Vereinigte Staaten
-
West Bloomfield, Michigan, Vereinigte Staaten
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten
-
-
North Carolina
-
Raleigh, North Carolina, Vereinigte Staaten
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten
-
Cleveland, Ohio, Vereinigte Staaten
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Vereinigte Staaten
-
-
Tennessee
-
Germantown, Tennessee, Vereinigte Staaten
-
-
Virginia
-
Norfolk, Virginia, Vereinigte Staaten
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten
-
-
-
-
-
Wien, Österreich
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- male/female
- 18 - 75 years inclusive
- diagnosis of Crohn's disease confirmed
- moderate to severe disease activity (Crohn's Disease Activity Index (CDAI) 225 - 450)
- no previous treatment with anti-tumor necrosis factor (anti-TNF) medications
Exclusion Criteria:
- previous participation in a certolizumab pegol study
- general exclusion criteria as common for studies in this indication
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Certolizumab pegol
Certolizumab pegol 400 mg for subcutaneous (sc) injection
|
Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
Andere Namen:
|
|
Placebo-Komparator: Placebo
Placebo, saline solution for sc injection
|
Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Subjects in Clinical Remission at Week 6
Zeitfenster: Week 6
|
The percentage of subjects in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Subjects Achieving a Clinical Response at Week 6
Zeitfenster: Week 0, Week 6
|
The percentage of subjects achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 6
Zeitfenster: Week 6
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 6 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 6
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 6
Zeitfenster: Week 0 to Week 6
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 6. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 6
|
|
Change in Harvey Bradshaw Index (HBI) Score From Week 0 to Week 6
Zeitfenster: Week 0 to Week 6
|
The change in Harvey Bradshaw Index (HBI) score from Week 0 to Week 6. HBI score consists of clinical parameters of general well-being (0 to 4), abdominal pain (0 to 3), number of liquid stools per day, abdominal mass (0 to 3), and complications (score 1 per item).
The first three items are scored for the previous day.
Lower scores indicated better well being.
|
Week 0 to Week 6
|
|
Percentage of Subjects in Clinical Remission at Week 2
Zeitfenster: Week 2
|
The percentage of subjects in clinical remission at Week 2 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 2
|
|
Percentage of Subjects in Clinical Remission at Week 4
Zeitfenster: Week 4
|
The percentage of subjects in clinical remission at Week 4 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 4
|
|
Percentage of Subjects Achieving a Clinical Response at Week 2
Zeitfenster: Week 0, Week 2
|
The percentage of subjects achieving a clinical response at Week 2 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 2
|
|
Percentage of Subjects Achieving a Clinical Response at Week 4
Zeitfenster: Week 0, Week 4
|
The percentage of subjects achieving a clinical response at Week 4 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 2
Zeitfenster: Week 0 to Week 2
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 2. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 2
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 4
Zeitfenster: Week 0, Week 4
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 4. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 2
Zeitfenster: Week 2
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 2 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 2
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 4
Zeitfenster: Week 4
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 4 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 4
|
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Zeitfenster: Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L of C-reactive Protein (CRP) at Entry who are in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Zeitfenster: Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Zeitfenster: Week 0, Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Zeitfenster: Week 0, Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3. doi: 10.1016/j.cgh.2011.04.031. Epub 2011 May 13.
- Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug;42(3):330-42. doi: 10.1111/apt.13251. Epub 2015 Jun 1.
- Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014 Oct;40(8):903-16. doi: 10.1111/apt.12930. Epub 2014 Aug 22.
Nützliche Links
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. März 2008
Primärer Abschluss (Tatsächlich)
1. Oktober 2009
Studienabschluss (Tatsächlich)
1. November 2009
Studienanmeldedaten
Zuerst eingereicht
18. Oktober 2007
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
31. Oktober 2007
Zuerst gepostet (Schätzen)
1. November 2007
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
9. August 2018
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
10. Juli 2018
Zuletzt verifiziert
1. Oktober 2011
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- C87085
- 2007-001913-41 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .